Really bio? You respond to ae kusterer, but not to my original post?
Poly-ICLC is a different company's DRUG. Not part of any natural dendritic cell maturation process. It works by pretending to be a VIRUS and stimulating other processes in the body when DCVax-L is injected. The entire notion is incorrect, and as I said, it is not in that particular patent that was referenced in the post to which I just previously referred. It's not included in any version of DCVax, either Direct or DCVax-L It's another company's carefully created, manufactured, drug and NWBO did not have a patent to make it any more than they had a patent to make Keytruda. They also have never claimed they make it nor that they sourced it from Uncover for their manufacturing.
I too, hope they coordinate and present trials with the combination in the future. The results are wonderful. But sometimes people make things up because they want to believe something. They get it in their head. Poly-ICLC is an adjuvant treatment in all of the trials. It is injected separately in an intramuscular injection. The UCLA formula for ATL-DC and DCVax-L are the same. There is no disconnection, as has been claimed by some shorts and so there is no need to further promote this false theory that will only create confusion as there is simply no basis to it.
No basis to this false theory huh? Okay, I’ll show you one of Northwest Bio’s patents for DCVax-Direct, and the part that states that poly I:C can be used as a maturation agent, and I won’t waste any more of my time on this:
OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE
One method to overcome this down regulation has been disclosed in WO 2004/053072 (incorporated herein by reference) where it was found that down regulation can be avoided through partial maturation of the DCs prior to administration. In this method dendritic cell precursors (bone marrow cells following red cell lysis or monocytic dendritic cell precursors) were induced in vitro to differentiate into immature dendritic cells and the immature dendritic cells were induced to begin maturation by culturing the cells with a dendritic cell maturation agent, such as BCG and IFN?, lipopolysaccharide (LPS), tumor necrosis factor a (TNFa), an imidazoquinoline compound, a synthetic double stranded polyribonucleotide, a agonist of a Toll-like receptor (TLR), a sequence of nucleic acids containing unmethylated CpG motifs known to induce the maturation of DC, or any combination thereof. The immature dendritic cells were allowed to continue maturation for a time period less than what had previously been determined for the immature dendritic cells to fully mature. If the dendritic cells were allowed to fully mature in vitro the cells would be unable to uptake and process antigen subsequent to administration to the patient. The inventors disclosed that the dendritic cells should be allowed to mature for 1 to about 10 hours for optimal activation prior to isolation of the partially mature dendritic cells and formulation for administration to a patient.
In the methods the dendritic cell maturation agent can be inactivated Bacillus Calmette-Guerin (BCG), interferon ? (IFN?), lipopolysaccharide (LPS), tumor necrosis factor a (TNFa), an imidazoquinoline compound, a synthetic double stranded polyribonucleotide, for example, poly I:C, a agonist of a Toll-like receptor (TLR), a sequence of nucleic acids containing unmethylated CpG motifs known to induce the maturation of dendritic cells, or any combination thereof. The inactivated BCG can comprise whole BCG, cell wall constituents of BCG, BCG-derived lipoarabidomannans, or BCG components and the inactivated BCG can be heat-inactivated, formalin-treated, heat-inactivated and formalin treated, and the like.
Claims
8. The method according to any one of claims 1 and 2, wherein the dendritic cell maturation agent is inactivated Bacillus Calmette-Guerin (BCG), interferon ? (IFN?), lipopolysaccharide (LPS), tumor necrosis factor a (TNFa), an imidazoquinoline compound, a synthetic double stranded polyribonucleotide, a agonist of a Toll-like receptor (TLR), a sequence of nucleic acids containing unmethylated CpG motifs known to induce the maturation of dendritic cells, or any combination thereof.
14. The method according to claim 8, wherein the synthetic double stranded polyribonucleotide is poly I:C.
